A

prominent Boston oncologist is downplaying comments he made at an invitation-only event last week that quickly spread among investors and set off alarm bells about an experimental multiple myeloma cell therapy from Bluebird Bio (BLUE) and Celgene (CELG).

Dr. Ken Anderson, a multiple myeloma expert at the Dana-Farber Cancer Institute, told investors attending the Cowen Health Care Conference on March 13 that three patients under his care suffered relapses after treatment with bb2121, the CAR-T therapy invented by Bluebird and licensed to Celgene.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.